BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 17036444)

  • 21. Innovation incentives or corrupt conflicts of interest? Moving beyond Jekyll and Hyde in regulating biomedical academic-industry relationships.
    Taylor PL
    Yale J Health Policy Law Ethics; 2013; 13(1):135-97. PubMed ID: 23815042
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gag clauses in clinical-trial agreements.
    Steinbrook R
    N Engl J Med; 2005 May; 352(21):2160-2. PubMed ID: 15917381
    [No Abstract]   [Full Text] [Related]  

  • 23. The academic/industry relationship: common misconceptions about bias.
    Cugini M
    J Dent Hyg; 2009; 83(4):208-9. PubMed ID: 19909651
    [No Abstract]   [Full Text] [Related]  

  • 24. Confronting the conflict of interest crisis in medical research.
    Lemmens T
    Monash Bioeth Rev; 2004 Oct; 23(4):19-40. PubMed ID: 15688510
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Industry-sponsored clinical research: a broken system.
    Angell M
    JAMA; 2008 Sep; 300(9):1069-71. PubMed ID: 18768418
    [No Abstract]   [Full Text] [Related]  

  • 26. Corporate Funding for Schools of Public Health: Confronting the Ethical and Economic Challenges.
    Bayer R; Sampat BN
    Am J Public Health; 2016 Apr; 106(4):615-8. PubMed ID: 26890166
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Data-sharing and data-withholding in genetics and the life sciences: results of a national survey of technology transfer officers.
    Campbell EG; Bendavid E
    J Health Care Law Policy; 2003; 6(2):241-55. PubMed ID: 15017960
    [No Abstract]   [Full Text] [Related]  

  • 28. Medical-research ethics under the microscope: schools try to plot the fine line between commercial links and conflicts of interest.
    Mangan KS
    Chron High Educ; 2003 Jul; 49(46):A22-4. PubMed ID: 15287130
    [No Abstract]   [Full Text] [Related]  

  • 29. Financial interests of authors in scientific journals: a pilot study of 14 publications.
    Krimsky S; Rothenberg LS; Stott P; Kyle G
    Sci Eng Ethics; 1996 Oct; 2(4):395-410. PubMed ID: 11657729
    [No Abstract]   [Full Text] [Related]  

  • 30. Sustainability and the balancing of the health care and innovation agendas: the commercialization of genetic research.
    Caulfield T
    Sask Law Rev; 2003; 66(2):629-45. PubMed ID: 15212021
    [No Abstract]   [Full Text] [Related]  

  • 31. A conflict of interest.
    Krimsky S
    New Sci; 2003 Aug; 179(2410):21. PubMed ID: 14982075
    [No Abstract]   [Full Text] [Related]  

  • 32. Participation of life-science faculty in research relationships with industry.
    Blumenthal D; Campbell EG; Causino N; Louis KS
    N Engl J Med; 1996 Dec; 335(23):1734-9. PubMed ID: 8929266
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Academic medical centers' standards for clinical-trial agreements with industry.
    Mello MM; Clarridge BR; Studdert DM
    N Engl J Med; 2005 May; 352(21):2202-10. PubMed ID: 15917385
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ethics and technology transfer: patients, patents, and public trust.
    Zucker D
    J Investig Med; 2011 Jun; 59(5):762-7. PubMed ID: 21346627
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ten steps to developing a national agenda to address financial conflicts of interest in industry sponsored clinical research.
    Tereskerz PM; Moreno J
    Account Res; 2005; 12(2):139-55. PubMed ID: 16220626
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The report of the committee of inquiry on the case involving Dr. Nancy Olivieri: a fiduciary law perspective.
    Litman M; Sheremeta L
    Health Law Rev; 2002; 10(2):3-13. PubMed ID: 15739307
    [No Abstract]   [Full Text] [Related]  

  • 37. Researcher said his colleague should have revealed possible conflicts of interest.
    Maloney DM
    Hum Res Rep; 2005 Jan; 20(1):8. PubMed ID: 15810184
    [No Abstract]   [Full Text] [Related]  

  • 38. Researchers' views of the acceptability of restrictive provisions in clinical trial agreements with industry sponsors.
    Mello MM; Clarridge BR; Studdert DM
    Account Res; 2005; 12(3):163-91. PubMed ID: 16634168
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lawmakers examine the possibility of favoritism in a $40-million NIH contract with Harvard.
    Brainard J
    Chron High Educ; 2003 Nov; 50(13):A19. PubMed ID: 15287136
    [No Abstract]   [Full Text] [Related]  

  • 40. All above board: openness is the only option if science is to maintain its integrity.
    New Sci; 2004 Mar 6-12; 181(2437):3. PubMed ID: 15139348
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.